Nordic group B.V – an international pharmaceutical company operating as Nordic Pharma have received CE mark approval for Lacrifill®, a novel dry eye therapy.
Lacrifill® is a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular system, preserving the tear film and offering long lasting effects of up to six months.
Following the launch of Lacrifill® in the United States last year, Nordic Pharma plans to expand its footprint in Europe, bringing this innovative dry eye solution to a broader patient population. Further details regarding availability and distribution will be shared closer to the launch date.
FURTHER INFORMATION:
For more information about Nordic Pharma, visit www.nordicpharma.com
